Clinical Trial Update: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 [Phase 2]

View source ↗

Summary

Phase 2 medical safety follow-up study of patients who received more than 28 days of exposure to BGG492; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Adenoma
• Endometrial Stromal Sarcoma

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas | Phase 2 | Status: COMPLETED | Results posted: 2016-07-25